+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. In 2016, the Chinese working group developed guidelines for the diagnosis and treatment of ADPKD, which promoted the clinical management of ADPKD in China. In the last 3 years, Chinese clinicians have deepened their understanding and standardized the management of ADPKD, and several basic and clinical studies on ADPKD have been conducted. In combination with international guidelines and research results, the working group updated the ADPKD guidelines in China. This guideline includes 5 chapters: introduction, diagnosis, kidney disease progression monitoring, treatment, and family planning. We highlight the main recommendations and suggestions of the ADPKD guidelines in this summary.

          Related collections

          Author and article information

          Kidney Diseases
          S. Karger AG
          May 2020
          19 March 2020
          : 6
          : 3
          : 144-149
          aDepartment of Nephrology, Changzheng Hospital, Second Military Medical University, Shanghai, China
          bDepartment of Nephrology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
          cDepartment of Nephrology, The Third Affiliated Hospital, Hebei Medical University, Shijiazhuang, China
          dDepartment of Nephrology, Peking Union Medical College Hospital, Beijing, China
          eDepartment of Nephrology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
          fDepartment of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
          gDepartment of Nephrology, Qilu Hospital, Shandong University, Jinan, China
          hDepartment of Nephrology, Guizhou Provincial People’s Hospital, Gui Yang, China
          iDepartment of Nephrology, Second Xiangya Hospital, Central South University, Changsha, China
          jDepartment of Nephrology, 900 Hospital of the Joint Logistics Team, PLA, Fuzhou General Clinical Medical College of Fujian Medical University, Fuzhou, China
          kDepartment of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
          lDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China
          mDepartment of Nephrology, The Third Affiliated Hospital, Peking University, Peking, China
          nSichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science, Chengdu, China
          Author notes
          *Chang-Lin Mei or Cheng Xue, Kidney Institute, Department of Nephrology, Changzheng Hospital, 415 Fengyang Rd., Shanghai 200003 (China), or
          506288 Kidney Dis 2020;6:144–149
          © 2020 The Author(s) Published by S. Karger AG, Basel

          This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Tables: 2, Pages: 6


          Comment on this article